Kevin DeGeeter

Stock Analyst at Oppenheimer

(1.71)
# 2,066
Out of 4,494 analysts
30
Total ratings
31.43%
Success rate
44.36%
Average return

26 Stocks

AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $2.72
Upside: +708.82%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $10.99
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30$24
Current: $2.01
Upside: +1,094.03%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $19.28
Upside: +408.30%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141$125
Current: $21.87
Upside: +471.56%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.90
Upside: -
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.68
Upside: -
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $1.50
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.19
Upside: -
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: n/a
Current: $338.50
Upside: -
Exact Sciences
Jul 29, 2021
Maintains: Outperform
Price Target: n/a
Current: $49.67
Upside: -
Sensei Biotherapeutics
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.72
Upside: -
Rezolute
May 27, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.78
Upside: -
Cyclacel Pharmaceuticals
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $1.73
Upside: +14,639.88%
Evaxion Biotech
Mar 2, 2021
Initiates: Outperform
Price Target: $180
Current: $3.10
Upside: +5,706.45%
Vericel
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $52.22
Upside: -
Taysha Gene Therapies
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.46
Upside: -
Rocket Pharmaceuticals
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $23.35
Upside: -
Cellectar Biosciences
Jul 1, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.79
Upside: -
Bionano Genomics
Apr 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.66
Upside: -
Interpace Biosciences
Jan 16, 2020
Maintains: Outperform
Price Target: n/a
Current: $1.10
Upside: -
Novavax
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $16.44
Upside: -
Molecular Templates
Aug 3, 2017
Initiates: Buy
Price Target: n/a
Current: $1.39
Upside: -
Cidara Therapeutics
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $12.94
Upside: +1,638.79%
Myriad Genetics
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $27.39
Upside: -
Codexis
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $3.71
Upside: -